Comprehensive Preclinical Development, DMPK, and Bioanalytical Solutions for Novel Peptide Therapeutics

DATE

July 10, 2025

TIME

8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST - Duration: 60 Minutes

Overview

In recent years, peptide therapeutics have garnered significant attention due to their remarkable potential in treating a wide range of human diseases, including diabetes, obesity, and cancer. Over 100 peptide drugs have been approved and marketed globally, highlighting their growing importance in modern medicine. However, the development of novel peptide therapeutics presents notable challenges. Their larger size and structural complexity pose unique difficulties in bioanalysis, such as non-specific binding, assay sensitivity, stability, and immunogenicity evaluations. Additionally, the diverse submodalities of therapeutic peptides result in distinct ADME properties, further complicating their preclinical development. Given the lack of specific guidelines and technical standards for non-clinical research on peptide drugs, a case-by-case approach is essential for preclinical toxicological evaluations. This involves designing studies based on the specific regulations outlined in various guidelines while considering the unique characteristics of each peptide drug. To address these challenges and accelerate the development process, comprehensive preclinical development, DMPK, and bioanalytical solutions are crucial.

This webinar will cover non-clinical safety evaluation strategies, DMPK assessment including radiolabeling synthesis and ADME studies, as well as solutions for bioanalytical challenges such as non-specific binding and immunogenicity, providing researchers with essential knowledge and tools.

Register now for the previous webinar in the series, July 9, 2025:

Integrated Screening & Assay Capability Facilitate Peptide Drug Early Discovery

Key Learning Objectives:

Non-clinical safety evaluation strategies, regulations and guidelines
Peptide radiolabeling synthesis considerations
Preclinical peptide ADME research in rodents and large animals
Solutions to bioanalytical challenges in peptide therapeutics: LC-MS/MS and immunogenicity assays

Who Should Attend:

Bioanalytical and DMPK professionals, including lab managers and LC-MS/MS or immunochemistry specialists
Clinical pharmacologists and drug development project managers
Researchers and developers focused on peptide therapeutics
Investors and analysts tracking peptide drug innovation and market potential

Brought to you by:

Speakers

Zhimei Wang
Director, Toxicology Department,
WuXi AppTec

Lingling Zhang, PhD
Director, DMPK Department,
WuXi AppTec

Wenzhong Liang, PhD
Executive Director, Bioanalytical Services Department,
WuXi AppTec

Melissa O'Meara
Forensic Science Consultant,
C&EN Media Group

Registration

Forwarded this event? Clear the form

Email Address*

Salutation

First Name*

Last Name*

Company*

Job Title*

City*

State*

Country/Territory/Area*

Business Phone*

What stage of development is your peptide program currently in?*

Which of the following areas are you most interested in?*

What are your biggest challenges in peptide drug development? (Select up to 2)*

I would like to receive C&EN’s weekly newsletter with the latest in chemistry news

I would like to receive more information on products and services from the American Chemical Society

address2

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

View On Demand Webinars